摘要
目的:评价国产奈达铂和氟尿嘧啶同期放化疗治疗Ⅲ、Ⅳa期鼻咽癌的局控率、生存率和毒副反应。方法:回顾性分析奈达铂+氟尿嘧啶同期放化疗治疗Ⅲ、Ⅳa期鼻咽癌30例的局控率、生存率和毒副反应,并与顺铂+氟尿嘧啶方案同期放化疗30例相比较。结果:CR率奈达铂组为93.33%,顺铂组为86.67%,两组比较差异无显著性意义(P>0.05);1年无复发生存率和1年无远处转移生存率奈达铂组分别为93.33%和86.67%,顺铂组分别为86.67%和80.00%,两组比较差异无显著性意义(P>0.05);治疗毒副反应:奈达铂组恶心呕吐低于顺铂组,尤其Ⅲ、Ⅳ度恶心呕吐奈达铂组明显降低(P<0.01);两组肝、肾、骨髓及Ⅲ、Ⅳ度皮肤、口腔黏膜的毒副反应比较差异无显著性意义(P>0.05)。结论:奈达铂+氟尿嘧啶同期放化疗治疗Ⅲ、Ⅳa期鼻咽癌近期疗效确切,毒副反应较低,患者耐受性良好。
Objective： To evaluate the rates of local control, survival and toxicity of nedaplatin and fluorouracil（5-Fu） chemotherapy in combination with radiotherapy for Stage Ⅲ and Ⅳa nasopharyngeal carcinoma（NPC）. Methods：The rates of local control, survival and toxicity of the 30 examples of nedaplatin and fluorouracil chemotherapy in combination with radiotherapy for Stage Ⅲ and Ⅳa nasopharyngeal carcinoma were examined and compared with the 30 examples of cisplatin and fluorouracil chemotherapy in combination with radiotherapy. Results：The complete remission （CR）rate in nedaplatin group was 93.33%. And in cisplatin group it was 86.67%. There wasno difference between them in statistics（P〉0.05）. The 1-year free from local regional failure survival rate and the 1-year free-distant metastasis survival rate of nedaplatin group were 93.33% and 86.67%. They were 86.67% and 80.00% in cisplatin group. Also there was no difference between them in statistics（P〉0.05）. Compare the side effects, the nausea in nedaplatin group was lower than that in cisplatin group,the nausea in nedaplatin group of Stage Ⅲ and Ⅳa reduced obviously（P〈0.01）. The side effects in liver, nephridium,medulla, the cutis of Stage Ⅲ and Ⅳa and the mucous membrane of nonnasality had no difference in statistics between the two groups （P〉0. 05）. Conclusions： Nedaplatin and 5-Fu chemotherapy combined with radiotherapy for nasopharyngeal carcinoma of stage Ⅲ and Ⅳa may be higher efficacy and lower toxicity,and most patients tolerate the therapy well.
出处
《实用临床医学（江西）》
CAS
2007年第1期106-108,共3页
Practical Clinical Medicine
关键词
鼻咽肿瘤
放射疗法
化学疗法
奈达铂
顺铂
nasopharyngeal carcinoma
radiotherapy
chemotherapy
nedaplatin
cisplatin
